iBio and Caliber Designate New Fusion Protein as Target Product Under License and Collaboration Agreement
January 15, 2014 08:31 ET
|
iBio, Inc.
NEWARK, DE--(Marketwired - Jan 15, 2014) - iBio, Inc. (NYSE MKT: IBIO) announced today that the company and Caliber Biotherapeutics have designated a proprietary fusion protein for cancer...